Lilly(Eli) & Company
NYSE: LLY
$797.45
+$21.07 (+2.7%)
Closing Price on November 7, 2024
LLY Articles
Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.
Published:
Credit Suisse sees solid upside in this company Eli Lilly as the result of a strong pipeline, with its Alzheimer's candidate as a potential blockbuster.
Published:
Friday's top analyst upgrades, downgrades and initiations include AT&T, BioCryst Pharmaceuticals, Eli Lilly, Facebook, Flextronics, Gap and Tesla Motors.
Published:
Wikimedia CommonsIf there was ever a time when investors are thrilled to see the calendar change it could be now. With the fourth quarter just starting, many are more than relieved to put the third...
Published:
After the worst quarter in the stock market in four years, a new research report from Merrill Lynch includes the firm's top 10 U.S. ideas for the fourth quarter.
Published:
The market volatility has left all investors a touch shaken, but the chatter of a bear market and a collapse ring pretty hollow when the economy is not in recession.
Published:
One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given a golden opportunity to buy the top companies at much better prices.
Published:
Merrill Lynch reiterated a Buy rating and price objective on Eli Lilly after positive data on its Jardiance.
Published:
The gut-wrenching drop back in August, when the Dow opened down 1,000 points and the indexes went through the first 10% correction in almost four years was, needless to say, an eye-opener for...
Published:
Friday’s top analyst upgrades, downgrades and initiations include Aetna, Eli Lilly, Gilead Sciences, Royal Gold and Sirius XM.
Published:
Eli Lilly shares got a solid boost in the market Thursday morning as the broad markets were selling off.
Published:
With Panera Bread out of the Merrill Lynch US 1 List, these dividend contrarian plays could make good sense now.
Published:
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall. One area that looks very...
Published:
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.
Published:
Eli Lilly reported better-than-expected second-quarter earnings Thursday before the markets opened.
Published: